TransMedics Group (TMDX) OCS Heart DBD Receives Broader Than Expected Label- Canaccord Genuity
Tweet Send to a Friend
Canaccord Genuity analyst Jason Mills reiterated a Buy rating and $79.00 price target on TransMedics Group (NASDAQ: TMDX) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
